• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Immunol Res . Phenotypic Alterations of CD8+ and CD8- CD56+ NK Cell Subsets in Moderate and Severe COVID-19 Disease

tetano

Editor, Senior Moderator
J Immunol Res

. 2026;2026(1):e8647361.
doi: 10.1155/jimr/8647361.

Phenotypic Alterations of CD8+ and CD8- CD56+ NK Cell Subsets in Moderate and Severe COVID-19 Disease​


Matyas Meggyes 1 , David U Nagy 2 , Ildiko Toth 3 , Livia Mezosi 1 , David Sipos 4 , Agnes Peterfalvi 5 , Laszlo Szereday 1

Affiliations Expand


Abstract​


The COVID-19 pandemic has created a global health challenge. Severe cases are associated with immune system dysfunction, which can lead to uncontrolled inflammation. There are no published data on the specific roles of natural killer (NK)-cell subsets and immune checkpoint (IC) molecules in disease severity. Thirty-five patients diagnosed with COVID-19 and 14 healthy controls were involved in the study. From peripheral blood, CD56dim and CD56bright cell subsets were analyzed by flow cytometry for the expression of IC molecules (T-cell immunoglobulin and ITIM domain [TIGIT], CD226, and PD-1), activation markers (CD69), and cytotoxic potential (CD107a degranulation, granzymes, and perforin content). In COVID-19 patients, the proportion of CD8- CD56dim cells was significantly higher than the CD8+ subset. Inhibitory receptors TIGIT and PD-1 exhibited significantly higher relative expression in CD8+ CD56dim cells compared to their CD8- counterparts across infected groups, an effect particularly pronounced in deceased patients. Conversely, activating CD226 expression was reduced in the CD8- CD56dim subset only in severe cases. Functional assays revealed significantly elevated CD107a and CD69 expression in CD56dim cells of patients versus controls. Notably, CD8- CD56bright cells from deceased patients demonstrated enhanced CD107a expression and elevated perforin content, suggesting a shift toward hyperactivation. The preferential upregulation of inhibitory checkpoint molecules on the highly active CD8+ subset may reflect a compensatory response to immune activation, whereas the enhanced activation of CD8- NK-cell subsets was associated with disease severity and mortality. Similarly, the heightened cytotoxic profile of CD8- CD56bright cells observed in fatal cases may reflect immune dysregulation associated with severe COVID-19.

Keywords: CD107a; CD8; COVID-19; NK cells; SARS-Cov-2; immune checkpoints.
 
Back
Top Bottom